The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Open accessAbstract
OBJECTIVE: To correlate different methods of measuring rates of brain atrophy from serial MRI with corresponding clinical change in normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with probable Alzheimer disease (AD). METHODS: One hundred sixty subjects were recruited from the Mayo Clinic Alzheimer's Disease Research Center and Alzheimer's Disease Patient Registry Studies. At baseline, 55 subjects were cognitively normal, 41 met criteria for MCI, and 64 met criteria for AD. Each subject underwent an MRI examination of the brain at the time of the baseline clinical assessment and then again at the time of a follow-up clinical assessment, 1 to 5 years later. The annualized changes in volume of four structures were measured from the serial MRI studies: hippocampus, entorhinal cortex, whole brain, and ventricle. Rates of change on several cognitive tests/rating scales were also assessed. Subjects who were classified as normal or MCI at baseline could either remain stable or convert to a lower-functioning group. AD subjects were dichotomized into slow vs fast progressors. RESULTS: All four atrophy rates were greater among normal subjects who converted to MCI or AD than among those who remained stable, greater among MCI subjects who converted to AD than among those who remained stable, and greater among fast than slow AD progressors. In general, atrophy on MRI was detected more consistently than decline on specific cognitive tests/rating scales. With one exception, no differences were found among the four MRI rate measures in the strength of the correlation with clinical deterioration at different stages of the disease. CONCLUSIONS: These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD. Estimated sample sizes required to power a therapeutic trial in MCI were an order of magnitude less for MRI than for change measures based on cognitive tests/rating scales.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationAccurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J. M., Matthews, P. M., Federico, A., & Stefano, N. D. (2002) · NeuroImage · doi:10.1006/nimg.2002.1040 · Cited by 2,013
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404
Self-citationMedial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., & Kokmen, E. (1997) · Neurology · doi:10.1212/wnl.49.3.786 · Cited by 1,128
Self-citationRates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Self-citationAging, Memory, and Mild Cognitive Impairment
Petersen, R. C., Kokmen, E., Waring, S. C., Smith, G. E., Ivnik, R. J., & Tangelos, E. G. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004717 · Cited by 895
Self-citationCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Cited by
Sorted by citations
Items 501–600 of 827
Goltermann, J., Redlich, R., Dohm, K., Zaremba, D., Repple, J., Flint, C., Grotegerd, D., Förster, K., Meinert, S., Enneking, V., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00552 · Cited by 18
Imaging in neurodegenerative disorders: recent studies
Walker, Z., & Walker, R. W. H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000184417.29082.ea · Cited by 15
Galli, G., Ragazzoni, A., & Viggiano, M. P. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.664 · Cited by 15
“Structural imaging revealed that MTL structures show atrophic changes in MCI patients [8], and that these changes are more relevant in converters compared with nonconverters [9].”
BackgroundPlatero, C. A., & Tobar, M. C. (2017) · Neuroinformatics · doi:10.1007/s12021-017-9323-3 · Cited by 16
“The analysis of the hippocampus is a very active field of research because it is one of the first structures where early Alzheimer’s disease (AD) pathology is observed (Jack et al. 2004).”
BackgroundNovel strategies for the prevention of dementia from Alzheimer's disease
Shineman, D. W., & Fillit, H. M. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/dwshineman · Cited by 15
“Alternatively, measurements of regional distribution of atrophy may be a more sensitive method to track early changes in the disease.(17,18) Fludeoxyglucose (FDG)-positron emission tomography (PET) scans, where blood flow and glucose utilization over different brain regions can be measured, may also provide useful inf…”
MethodHippocampal atrophy in the healthy is initially linear and independent of age
Cohen, R. M., Szczepanik, J. E., McManus, M., Mirza, N., Putnam, K. T., Levy, J., & Sunderland, T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.018 · Cited by 15
Sachdev, P. S. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000577 · Cited by 13
Koike, R., Soeda, Y., Kasai, A., Fujioka, Y., Ishigaki, S., Yamanaka, A., Takaichi, Y., CHAMBERS, J. K., Uchida, K., Watanabe, H., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad359 · Cited by 17
“3,4 5-7 Because NFTs accumulate in the EC before memory problems, 7,8 the early identification of NFTs in the EC may be useful for the prevention of Alzheimer’s disease.”
BackgroundBiomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Automated algorithm to measure changes in medial temporal lobe volume in Alzheimer disease
Kazemifar, S., Drozd, J. J., Rajakumar, N., BORRIE, M. J., & Bartha, R. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.01.033 · Cited by 15
Correlation between baseline regional gray matter volume and global gray matter volume decline rate
Taki, Y., Kinomura, S., Sato, K., Goto, R., Wu, K., Kawashima, R., & Fukuda, H. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.09.071 · Cited by 14
The effects of sequential treatments on hippocampal volumes in malignant glioma patients
Nolen, S. C., Lee, B., Shantharam, S., Yu, H. J., Su, M., Billimek, J., & Bota, D. A. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2188-8 · Cited by 14
Stonnington, C. M., Chen, Y., Savage, C. R., Lee, W., Bauer, R. J., III, Sharieff, S., Thiyyagura, P., Alexander, G. E., Caselli, R. J., Locke, D. E. C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170852 · Cited by 14
“…PET measured glucose metabolism reductions in posterior cingulate [8], medial temporal [11], parietal regions [11], hippocampus [10], and entorhinal cortex [9] or MRI measures of hippocampus [7, 12, 15], entorhinal cortex [5, 15], medial temporal lobe [7, 13], and temporal lobe thickness [6, 14].”
Pan, F., Huang, Q., Huang, C., Lu, Y. W., Cui, L., Huang, L., Guan, Y., Xie, F., & Guo, Q. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70005 · Cited by 13
“35,36 In addition, changes in CSF tau levels show a weak link to cognitive impairment in late-stage AD patients.”
Nutritional intervention for diabetes mellitus with Alzheimer's disease
Li, Z., Li, S., Xiao, Y., Zhong, T., Yu, X., & Wang, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1046726 · Cited by 12
“Brain atrophy is accelerated in the elderly with cognitive impairment, particularly those who have AD (104).”
BackgroundSchoemaker, D., Buß, C., Pietrantonio, S., Maunder, L., Freiesleben, S. D., Hartmann, J., Collins, D. L., LUPIEN, S. J., & Pruessner, J. C. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116108 · Cited by 13
Le, X. T., Nguyen, H. T., Nguyen, T. V., Pham, H. T. N., Nguyen, P. T., Nguyen, K. M., Nguyen, B. V., & Matsumoto, K. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6627648 · Cited by 14
“Evidence indicates that hemispheric atrophy due to ventricular enlargement is correlated with cognitive dysfunction [35] and increased incidences of senile plaques and neurofibrillary tangles in AD patients [36].”
BackgroundBlood Pressure and Progression of Cerebral Atrophy in Patients With Vascular Disease
Vlek, A. L. M., Visseren, F. L. J., Kappelle, L. J., Geerlings, M. I., Vincken, K. L., Mali, W. P. T. M., & van der Graaf, Y. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.166 · Cited by 13
Palanisamy, R., Sundar, S., & Ramakrishnan, S. (2019) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2019.03.003 · Cited by 14
Neuroimaging Biomarkers in Alzheimer's Disease
Chong, M. S., & Lim, W. S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9831-4_1 · Cited by 13
Subcortical morphological correlates of impaired clock drawing performance
Seidl, U., Traeger, T., Hirjak, D., Remmele, B., Wolf, R. C., Kaiser, E., Stieltjes, B., Essig, M., Schröder, J., & Thomann, P. A. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.01.054 · Cited by 13
Structural imaging markers for therapeutic trials in Alzheimer's disease
Fox, N. C., & Kennedy, J. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0040-y · Cited by 13
“…duration 100-200 subjects per arm completing the trial with adequate scans seems to be sufficient to give 90% power to detect a 20% slowing of hippocampal or whole brain atrophy – these are much smaller numbers than would be required to show a similar effect size with a clinical outcome (7, 15).”
Is Mild Cognitive Impairment a Valid Target of Therapy
Rockwood, K. J., Chertkow, H. M., & Feldman, H. (2007) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100005643 · Cited by 13
Li, H., Zou, L., Shi, J., & Han, X. (2021) · Hereditas · doi:10.1186/s41065-021-00190-0 · Cited by 12
Brain ventricles, CSF and cognition: a narrative review
Júnior, M. L. D. M. S., Diniz, P. R. B., Vilanova, M. V. D. S., Basto, G. P. T., & Valênça, M. M. (2022) · Psychogeriatrics · doi:10.1111/psyg.12839 · Cited by 15
Metformin use and brain atrophy in nondemented elderly individuals with diabetes
Nabizadeh, F., Kankam, S. B., Balabandian, M., Hashemi, S. M., Sharifkazemi, H., & Rostami, M. R. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111890 · Cited by 15
Hippocampus substructure segmentation using morphological vision transformer learning
Lei, Y., Ding, Y., Qiu, R. L. J., Wang, T., Roper, J. R., Fu, Y., Shu, H. G., Mao, H. Z., & Yang, X. (2023) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ad0d45 · Cited by 12
Image processing: an early detection tool for Alzheimer’s disease
Ballav, S., Biswas, B., Dey, S., Sahu, V. K., & Basu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00001-6 · Cited by 13
A quantitatively interpretable model for Alzheimer’s disease prediction using deep counterfactuals
Oh, K., Heo, D.-W., Mulyadi, A. W., Jung, W., Kang, E., Lee, K. H., & Suk, H. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121077 · Cited by 12
Puzio, T., Matera, K., Karwowski, J., Piwnik, J., Białkowski, S., Podyma, M., Dunikowski, K., Siger, M., Stasiołek, M., Grzelak, P., et al. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.04.007 · Cited by 14
“…and right, respectively, for 1.5 T) and 1.84 % and 2.32 % (left and right, respectively, for 3 T), which remains lower than the estimated annual-ized rate of hippocampal atrophy reported in AD patients — 3.0 % and 3.6 % for slow and fast progressors, respectively, as reported by Jack et al. [15].”
InfluentialNeuroimaging Biomarkers in Alzheimer’s Disease
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00003-1 · Cited by 11
Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients
de Vos, F., Schouten, T. M., Koini, M., Bouts, M. J. R. J., Feis, R. A., Lechner, A., Schmidt, R., van Buchem, M. A., Verhey, F. R. J., Rikkert, M. G. M. O., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102303 · Cited by 12
Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
Li, X., Ba, M., Ng, K. P., Mathotaarachchi, S. S., Pascoal, T. A., Rosa‐Neto, P., Gauthier, S. G., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.08.001 · Cited by 13
The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale
Šilhán, D., Bartoš, A., Mrzílková, J., Pashkovska, O., Ibrahim, I., & Tintěra, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200807193957 · Cited by 12
“Tissue loss in mediotemporal area is typical for late-onset AD (patients older than 65 years) [7-13].”
Yoshiura, T., Hiwatashi, A., Yamashita, K., Ohyagi, Y., Monji, A., Takayama, Y., Kamano, N., Kawashima, T., Kira, J. I., & Honda, H. (2010) · European Radiology · doi:10.1007/s00330-010-1939-8 · Cited by 12
Aβ(42) induced MRI changes in aged rabbit brain resembles AD brain
Ramesh, B. N., Raichurkar, K. P., Shamasundar, N. M., Rao, T. S., & Rao, K. S. J. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.06.003 · Cited by 10
Magnetic Resonance Imaging Findings Among Individuals With Olfactory and Cognitive Impairment
Yi, J. S., Hura, N., Roxbury, C. R., & Lin, S. Y. (2021) · The Laryngoscope · doi:10.1002/lary.29812 · Cited by 12
Morin, J., Mouiha, A., Pietrantonio, S., Duchesne, S., & Hudon, C. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345234 · Cited by 13
Structural imaging in early pre-states of dementia
Smith, C. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.002 · Cited by 11
Ünay, D. (2012) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2012.03.006 · Cited by 11
Verclytte, S., Lopes, R., Delmaire, C., Ferré, J., Pasquier, F., & Leclerc, X. (2015) · European Radiology · doi:10.1007/s00330-015-3652-0 · Cited by 11
“Structural MRI is an essential tool for the assessment of AD, allowing the detection of areas of atrophy typically located in the medial temporal lobes and the neocortical temporoparietal cortex [1–6].”
MethodMenéndez‐González, M., Suárez-Sanmartín, E., García, C., Martínez‐Camblor, P., Westman, E., & Simmons, A. (2016) · Cureus · doi:10.7759/cureus.544 · Cited by 11
Positron Emission Tomography Diagnosis of Alzheimer's Disease
Coleman, R. E. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.09.003 · Cited by 12
“MR imaging and CT are performed in the evaluation of patients who have suspected early AD, but these imaging studies are neither sensitive nor specific for the diagnosis of AD [1,2,4].”
MethodNutrient Biomarker Patterns, Cognitive Function, and Mri Measures of Brain Aging
Annweiler, C., Montero‐Odasso, M., Bartha, R., & Beauchet, O. (2012) · Neurology · doi:10.1212/01.wnl.0000414241.41860.13 · Cited by 11
High pulse pressure is a risk factor for prodromal Alzheimer’s disease: a longitudinal study
Shi, W., Initiative, A. D. N., Wang, Z.-T., Sun, F.-R., Ma, Y., Xu, W., Shen, X., Dong, Q., Tan, L., Yu, J., et al. (2020) · Aging · doi:10.18632/aging.103678 · Cited by 10
Pathology steered stratification network for subtype identification in Alzheimer's disease
Xu, E., Zhang, J., Li, J., Song, Q., Yang, D., Guorong Wu, A., & Chen, M. (2023) · Medical Physics · doi:10.1002/mp.16655 · Cited by 10
3D scattering transforms for disease classification in neuroimaging
Adel, T., Cohen, T., Caan, M. W. A., & Welling, M. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.02.004 · Cited by 10
Multi-Modality Sparse Representation for Alzheimer’s Disease Classification
Kwak, K., Initiative, A. F. T. A. D. N., Yun, H. J., Park, G., & Lee, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170338 · Cited by 10
“Inparticular,thehippocampusis oneofthemostimportantstructuresrelatedtoAD [29]andMCI[30],andmanystudieshaveused the hippocampus to discriminate between patients with AD/MCI and controls.”
Šilhán, D., Initiative, A. D. N., Pashkovska, O., & Bartoš, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210372 · Cited by 10
Preclinical characterization of amyloid imaging probes with multiphoton microscopy
Skoch, J. M., Hyman, B. T., & Bacskai, B. J. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s345 · Cited by 10
Differentiating Dementia With Lewy Bodies and Alzheimer’s Disease Using MRI
Watson, R., & O'Brien, J. T. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.41 · Cited by 9
Bayón, F. C., Maese, J., Fernández-Oliveira, A., Uzal, T. M., Herrera, E., N, T., & Menéndez‐González, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00305 · Cited by 10
“Age-associated differences are detected in the MTL with an acceleration of Medial Temporal Lobe Atrophy (MTA) starting around 72 years of age in healthy people (Jack et al., 2004; Salk et al., 2014).”
BackgroundSidiropoulos, C., Jafari‐Khouzani, K., Hamid Soltanian-zadeh, A., Mitsias, P. D., Alexopoulos, P., Richter‐Schmidinger, T., Reichel, M., Lewczuk, P., Doerfler, A., & Kornhuber, J. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00546.x · Cited by 11
Kincses, Z. T., Király, A., Veréb, D., & Vécsei, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143195 · Cited by 10
Biomechanical perspectives on traumatic brain injury in the elderly: a comprehensive review
Abdi, H., Sánchez‐Molina, D., Vilana, S. G., & Rahimi-Movaghar, V. (2025) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ada654 · Cited by 9
“Additionally, hippocampal atrophy rates of − 3 to − 8% per year have been documented in some studies [60, 61, 64].”
Remote cognitive tests predict neurodegenerative biomarkers in the Insight 46 cohort
Giovane, M. D., Giunchiglia, V., Cai, Z., Leoni, M., Street, R. E., Lu, K., Wong, A., Popham, M., Nicholas, J. M., Trender, W. R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14572 · Cited by 10
Immediate ROI Search for 3-D Medical Images
Simonyan, K., Marc Modat, A., Sebastien Ourselin, A., Cash, D. M., Criminisi, A., & Zisserman, A. (2013) · Lecture notes in computer science · doi:10.1007/978-3-642-36678-9_6 · Cited by 9
“Structural MRI data has been shown to provide reliable quantification of the atrophy process in the brain caused by Alzheimer’s disease (AD) [5] or other neurodegenerative disorders.”
BackgroundWang, Z.-T., Initiative, A. D. N., Chen, S.-D., Xu, W., Chen, K., Wang, H.-F., Tan, C., Cui, M., Dong, Q., Tan, L., et al. (2019) · Aging · doi:10.18632/aging.102066 · Cited by 9
Yu, G.-X., Initiative, A. D. N., Zhang, T., Hou, X., Ou, Y., Hu, H., Wang, Z.-T., Guo, Y., Xu, W., Tan, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201117 · Cited by 9
Wu, L., Wang, X., Ye, Y., & Liu, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.664443 · Cited by 8
“In addition, rates of change in several brain regions, such as entorhinal cortex (Cardenas et al., 2011), hippocampus (Jack et al., 2004), ventricular enlargement (Ridha et al., 2008), and whole-brain (Sluimer et al., 2010), have been reported to be associated with changes in cognitive performance,…”
BackgroundMadsen, S. K., Steeg, G. V., Mezher, A. F., Jahanshad, N., Nir, T. M., Hua, X., Gutman, B. A., Galstyan, A., & Thompson, P. M. (2015) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2015.7164035 · Cited by 9
“perhaps because brain atrophy is a more stable measure[15].”
BackgroundLa neuro-imagerie au service de la maladie d’Alzheimer
Chételat, G. (2011) · médecine/sciences · doi:10.1051/medsci/2011272193 · Cited by 13
“Plusieurs études ont montré la sensibilité de l’IRM pour détecter l’évolution de l’atrophie au cours du temps, en particulier le taux d’atrophie de l’hippocampe ou de la substance grise globale [17, 18], et ces mesures sont déjà utilisées dans des études thérapeutiques.”
Eyes on the prize: Federal Alzheimer's research effort aims to facilitate interventions
Hodes, R. J., Buckholtz, N. S., Cahan, V., & Morrison‐Bogorad, M. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.11.002 · Cited by 9
Liver Isolation in Abdominal MRI
Logeswaran, R., Haw, T. W., & Sarker, M. S. Z. (2008) · Journal of Medical Systems · doi:10.1007/s10916-008-9131-2 · Cited by 9
“There have been numerous advances related to other organs when it comes to automatic processing of MRI, such as brain [16] and heart [17], but significantly less work has been done for the liver using the same modality.”
BackgroundGomez, C. L., Ortiz-Ramón, R., Mollá, E., Moratal, D., & Initiative, A. D. N. (2018) · Diagnostics · doi:10.3390/diagnostics8030047 · Cited by 10
“In particular, structural magnetic resonance imaging (MRI) has gained more attention than other imaging techniques because it makes it possible to visualize in life the progressive cerebral atrophy that characterizes the neurodegenerative process of dementia, thus contributing to improving diagnostic accuracy [4,11,12…”
BackgroundHippocampus analysis based on 3D CNN for Alzheimer’s disease diagnosis
Cui, R., & Liu, M. (2018) · International Conference on Digital Image Processing · doi:10.1117/12.2503194 · Cited by 9
Diagnostic imaging devices in Alzheimer’s disease
Jelić, V., & Wahlund, L. (2007) · Expert Review of Medical Devices · doi:10.1586/17434440.4.4.475 · Cited by 9
Carotenuto, A., Andreone, V., Amenta, F., & Traini, E. (2024) · Medicina · doi:10.3390/medicina60060925 · Cited by 8
Cross‐Dataset Evaluation of Dementia Longitudinal Progression Prediction Models
Zhang, C., An, L., Wulan, N., Nguyen, K., Orbán, C., Chen, P., Chen, C., Zhou, J. H., Liu, K., Yeo, B. T. T., et al. (2025) · Human Brain Mapping · doi:10.1002/hbm.70280 · Cited by 9
“There have been studies that converted longitudinal MRI histories into brain atrophy rates (Jack et al. 2004; Chincarini et al. 2016), but FROG's L2C transformation captured a richer set of temporal statistics, such as past maximum and past minimum, in addition to the rate of change (Section 2.6).”
InfluentialBansal, R., Hao, X., Liu, J., & Peterson, B. S. (2014) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2014.07.011 · Cited by 8
“Supervised machine learning algorithms 1–15 use known clinical diagnoses for participants to learn classification boundaries that best separate in feature space the brain imaging measures of participants who have different diagnoses.”
BackgroundIn vivo magnetic resonance approach to trimethyltin induced neurodegeneration in rats
Bačiak, L., Gáspárová, Z., Liptaj, T., & Juránek, I. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.012 · Cited by 8
Modified Visual Magnetic Resonance Rating Scale for Evaluation of Patients with Forgetfulness
Yalçiner, B., Kandemir, M., Taskale, S., Tepe, S. M., & Ünay, D. (2018) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.333 · Cited by 8
“It has been shown that MTA, VA, and SA increase over time in AD patients,(3,28) whereas SA and VA better correlate with changes in neuropsychometric tests than MTA.(3) In our study, especially high VAs, MTAs, and Ts are also found to be significant in terms of degenerative process.”
BackgroundCase Study: A Precision Medicine Approach to Multifactorial Dementia and Alzheimer's Disease.
Ross, M. K., Raji, C. A., Lokken, K., Bredesen, D. E., Roach, J. C., Funk, C. C., Price, N. D., Rappaport, N., Hood, L., & Heath, J. R. (2021) · PubMed · Cited by 12
Duara, R., Loewenstein, D., Shen, Q., Barker, W., Greig, M. T., Varón, D., Murray, M. E., & Dickson, D. W. (2013) · Advances in Alzheimer s Disease · doi:10.4236/aad.2013.24019 · Cited by 9
“Structural MRI has been shown to be one of the best and most readily available measures to assess the biological heterogeneity and rate of progression of AD [3].”
BackgroundNestor, S. M., Rupsingh, R., Accomazzi, V., BORRIE, M. J., Smith, M., Wells, J., & Bartha, R. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.04.305 · Cited by 8
Chen, T., Zhu, J., Tsai, S., & Yang, A. C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01448-1 · Cited by 8
Wang, X., Ye, T., Jiang, D., Zhou, W., Zhang, J., & Initiative, A. D. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1410544 · Cited by 7
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 12
“31,32”
Sakurai, K., Kaneda, D., Inui, S., Uchida, Y., Morimoto, S., Nihashi, T., Kato, T., Ito, K., & Hashizume, Y. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210043 · Cited by 7
“Somestudies havesuggestedtheutilityofventricularenlargement asameasureofADprogression[35,36].”
Fernández‐Viadero, C., González‐Mandly, A., Verduga, R., Crespo, D., & Cruz-Orive, L. M. (2008) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(08)71147-8 · Cited by 7
Landmark-Based Alzheimer’s Disease Diagnosis Using Longitudinal Structural MR Images
Zhang, J., Liu, M., An, L., Gao, Y., & Shen, D. G. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-61188-4_4 · Cited by 7
“, hippocampus, entorhinal cortex, whole brain and ventricle), and supported the idea of using changing rates as biomarkers for AD diagnosis [16].”
BackgroundClassification of MRI and psychological testing data based on support vector machine.
Yang, W., Chen, X., Cohen, D. S., Rosin, E. R., Toga, A. W., Thompson, P. M., & Huang, X. (2017) · PubMed · Cited by 7
Progression of Atrophy in Alzheimer’s Disease and Related Disorders
Whitwell, J. L. (2010) · Springer eBooks · doi:10.1007/978-1-4614-0785-0_15 · Cited by 8
Schmidt, R., Havas, D., Ropele, S., Enzinger, C., & Fazekas, F. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.003 · Cited by 7
Focus on Alzheimer's Disease and Related Disorders
Reiman, E. M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0701 · Cited by 7
Virtual reality navigation for the early detection of Alzheimer’s disease
Shima, S., Ohdake, R., Mizutani, Y., Tatebe, H., Koike, R., Kasai, A., Bagarinao, E., Kawabata, K., Ueda, A., Ito, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1571429 · Cited by 7
Structural Magnetic Resonance Imaging-Derived Biomarkers for Alzheimer's Disease
Barnes, J., Foster, J., & Fox, N. C. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.79 · Cited by 6
“Such analysis is important, since there is some evidence that change in MRI-atrophy rates may correlate better with disease progression than change on cognitive tests or clinical rating scales [48].”
BackgroundResultInfluentialClinical predictors of Alzheimer's disease progression
Hishikawa, N., Fukui, Y., Takemoto, M., Sato, K., Shang, J., Yamashita, T., Ohta, Y., & Abe, K. (2018) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13286 · Cited by 6
Barber, P., Schaeffer, M. J., & Chan, L. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303011 · Cited by 6
Jang, J., Kim, J., Park, S.-W., Kasani, P. H., Kim, Y., Kim, S., Kim, S.-J., Na, D. L., Moon, S. H., Seo, S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18696-6 · Cited by 6
Zhang, X., Meirelles, O., Li, Z., Yaffe, K. S., Bryan, R. N., Qiu, C., & Launer, L. J. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1110553 · Cited by 6
A linear primal–dual multi-instance SVM for big data classifications
Brand, L., Seo, H., Baker, L. Z., Ellefsen, C., Sargent, J., & Wang, H. (2023) · Knowledge and Information Systems · doi:10.1007/s10115-023-01961-z · Cited by 6
“The change in venticular volume is also associated with the cognitive decline and dementia [55, 56].”
Tico, M. (2009) · InTech eBooks · doi:10.5772/7458 · Cited by 6
Alzheimer’s Amyloidopathy: An Alternative Aspect
Regland, B., & McCaddon, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181007 · Cited by 6
MacLennan, T., Seres, P., Rickard, J. N., Stolz, E., Beaulieu, C., & Wilman, A. H. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.29011 · Cited by 6
Zhu, D. C., Gwo, C., Deng, A., Scheel, N., Dowling, M. A., Zhang, R., & Initiative, A. D. N. (2022) · Human Brain Mapping · doi:10.1002/hbm.26130 · Cited by 6
“Among the various brain regions, hippocampus volume reduction was found to be a sensitive and reliable imaging biomarker to monitor clinical AD progression (Jack et al., 1999, 2004, 2005).”
BackgroundFDG PET in the Evaluation of Mild Cognitive Impairment and Early Dementia
Mosconi, L., & Silverman, D. H. S. (2009) · Springer eBooks · doi:10.1007/978-0-387-76420-7_3 · Cited by 6
Matsuda, H. (2006) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.62.1066 · Cited by 6
Huang, L., Zhang, Y., Peng, Y., Zhao, Z., Zhou, Y., Wang, X., & Peng, Y. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05251-x · Cited by 6
Simulation of Local and Global Atrophy in Alzheimer’s Disease Studies
Cámara, Ó., Schweiger, M. J., Scahill, R. I., Crum, W. R., Schnabel, J. A., Hill, D., & Fox, N. C. (2006) · Lecture notes in computer science · doi:10.1007/11866763_115 · Cited by 6
“for hippocampus and brain) and study durations [11,12] of 6-24 months Figure 3 shows the difference images between the normal aging and the AD simulated images at each timepoint.”
Background
Metadata
- Authors
- Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., Tangalos, E. G., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2004-02-24
- Volume
- 62
- Issue
- 4
- Pages
- 591-600
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2730165
- OpenAlex
- W2005133023
- Cited by
- 827
- References
- 41
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 21 · 2023: 25 · 2022: 20 · 2021: 36 · 2020: 27 · 2019: 38 · 2018: 36 · 2017: 37 · 2016: 33 · 2015: 39 · 2014: 41 · 2013: 48 · 2012: 38
- FWCI
- 28.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (AG-06786, AG 16574, U01AG006786, R01AG011378, AG-11378, U19AG010483, R37AG011378, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, brain atrophy rate, serial MRI, hippocampal atrophy, entorhinal cortex atrophy, whole brain atrophy, ventriculomegaly, mild cognitive impairment, disease progression, surrogate markers, cognitive decline, trial size, MCI conversion
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Atrophy, Brain, Cognition Disorders, Female, Hippocampus, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Cohort Studies, Disease Progression, Entorhinal Cortex, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
